imatinib · IMATINIB MESYLATE 100 mg/1 · Tablet, Film Coated · Oral · Mylan Institutional Inc
NDC 42292-0043-03 · 30 BLISTER PACK in 1 CARTON / 1 TABLET, FILM COATED in 1 BLISTER PACK · ANDA · View full market →
4 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 37% in a year, to $0.6114 per unit — and generics that get this cheap tend to get abandoned rather than defended. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Golden State Medical Supply, Inc. | IMATINIB MESYLATE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | IMATINIB MESYLATE 400 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Institutional Inc | IMATINIB MESYLATE 400 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Institutional Inc | IMATINIB MESYLATE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Pharmaceuticals Inc. | IMATINIB MESYLATE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Pharmaceuticals Inc. | IMATINIB MESYLATE 400 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Safecor Health, LLC | IMATINIB MESYLATE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Safecor Health, LLC | IMATINIB MESYLATE 400 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Imatinib Mesylate — NDC 42292-0043-03," retrieved September 3, 2026, https://drugdashboards.com/drug/42292004303.
Free to cite with attribution — see how the data is put together.